<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281916</url>
  </required_header>
  <id_info>
    <org_study_id>2013_02</org_study_id>
    <secondary_id>2013-000595-15</secondary_id>
    <nct_id>NCT02281916</nct_id>
  </id_info>
  <brief_title>Safety Study of P28GST Treatment in Crohn's Disease Patients</brief_title>
  <acronym>ACROHNEM</acronym>
  <official_title>Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Agency, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter phase 2 clinical trial is designed to assess safety of P28GST (protein 28 Kd&#xD;
      glutathion S Transferrase), aiming to control inflammation in moderate Crohn's Disease (CD),&#xD;
      before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from&#xD;
      Schistosoma with potent immunogenic and anti-oxidant properties. Based on experimental&#xD;
      evidence of its anti-inflammatory properties, the investigators hypothesized that&#xD;
      administration of P28GST could protect against recurrence after intestinal resection surgery&#xD;
      in CD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study.&#xD;
      CD patients will be included after intestinal resection surgery or in moderate Crohn's&#xD;
      Disease (CD). Drug therapy will consisted in 3 injections of 100 µg of P28GST within 3 months&#xD;
      (one injection per month). The main objective of this study is to follow-up monthly rate and&#xD;
      seriousness of adverse events during one year. Secondary objectives are to control&#xD;
      immunologic and inflammatory blood and tissue markers, appearance or not of a clinical&#xD;
      recurrence assessed by CDAI (Crohn Disease Activity Index).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants wtih adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to one year</time_frame>
    <description>Clinical and blood markers change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main immunologic and inflammatory blood and tissue markers.</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index) and confirmed by a morphologic examination.</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>at inclusion, at 4 month , at 12 month</time_frame>
    <description>Evolution of bacterial species by genomic analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Crohn's Ileocolitis</condition>
  <arm_group>
    <arm_group_label>P28GST treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P28GST as a parasite enzyme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P28GST</intervention_name>
    <description>3 injections of 100 µg of P28GST within 3 months (one injection per month)</description>
    <arm_group_label>P28GST treatment</arm_group_label>
    <other_name>immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between the ages of ≥18 years at inclusion.&#xD;
&#xD;
          -  Subjects with ileal or ileo-colic CD without fistula&#xD;
&#xD;
          -  Subjects operated or not&#xD;
&#xD;
          -  CDAI score &lt; 220&#xD;
&#xD;
          -  no concomitant treatment excepted salicylates&#xD;
&#xD;
          -  Women of child bearing potential must be negative for pregnancy prior to study&#xD;
             enrolment&#xD;
&#xD;
          -  contraceptive means : females of childbearing potential as well as males are required&#xD;
             to use adequate contraceptive methods for 6 months starting at the inclusion, i;e 4&#xD;
             months after the 3rd injection .&#xD;
&#xD;
          -  No tobacco consumption (end date of tobacco consumption 8 days before surgery).&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
          -  French social security coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who use of azathioprine, anti-TNF (Tumor Necrosis Factor), methotrexate,&#xD;
             Vedolizumab, Ustekinumab and other immunosuppressors for 8 weeks before first&#xD;
             injection of P28GST&#xD;
&#xD;
          -  Subject who use of corticosteroids for 15 days before first injection of P28GST&#xD;
&#xD;
          -  Subject with history of vaccine hyper sensitivity or allergy.&#xD;
&#xD;
          -  Subject with any other clinical manifestation determined by the investigator&#xD;
&#xD;
          -  Subject wih AIDS, B or C hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique DEPLANQUE, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lille University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Boulogne</name>
      <address>
        <city>Boulogne sur mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier,</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Helminth antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

